, the supply of antimonial drugs to Amudat Hospital, in north-eastern Uganda, was interrupted and all cases of visceral leishmaniasis presenting at the hospital could only be treated with amphotericin B deoxycholate (AmB). This allowed the safety and effectiveness of the AmB to be evaluated, in comparison with an historical cohort of patients treated, at the same hospital, with meglumine antimoniate (Sb V ). Demographic and clinical data were collected before and after treatment. Adverse effects were recorded passively in all the subjects, and actively, using a standardized questionnaire, in a sub-group of the patients given AmB. The inhospital case-fatality 'rates' were 4.8% [95% confidence interval (CI)52.4%-8.8%] among the 210 patients treated with AmB and 3.7% (CI51.4%-7.9%) among the 161 patients treated with Sb V (P.0.20). Adverse effects requiring treatment interruption were rare in both cohorts. Treatment failures (i.e. non-responses or relapses) were observed in 2.9% (CI51.2%-6.4%) of the patients treated with AmB and 1.2% (CI50.1%-4.4%) of the patients treated with Sb V (P.0.20). For the treatment of visceral leishmaniasis in Uganda, AmB therefore had a similar effectiveness and safety profile to that of meglumine antimoniate.
Human visceral leishmaniasis (VL), or kalaazar, is a life-threatening haemo-protozoal disease, with an estimated 500,000 new cases occurring every year world-wide (WHO, 1997) . Treatment of VL remains a major problem, especially in resourcepoor areas (Guerin et al., 2002 ; GlaxoSmithKline, Brentford, U.K.) is limited, mainly because of high costs. The generic form of sodium stibogluconate (SSG), as manufactured by Albert David Ltd in Calcutta, India, has substantially reduced the cost of treatment and appears similar, in terms of safety and efficacy, to the branded drugs (Veeken et al., 2000; Moore et al., 2001; Ritmeijer et al., 2001; Bermú dez et al., 2006) . Unfortunately, this generic SSG is still not authorized for importation into many countries. In the treatment of VL, amphotericin B, either in its conventional form (amphotericin B deoxycholoate) or liposomal form, is a useful alternative to antimonial drugs (Sundar et al., 2004) . Amphotericin B deoxycholate (AmB) is now used as a first-line drug in the Indian state of Bihar, where resistance to antimonials has become a major problem (Mishra et al., 1994; Thakur and Narayan, 2004) , and as a second-line drug in some Latin American (Santos et al., 2002) and Asian countries, such as Nepal (Rijal et al., 2003) . In India, AmB has been found to be effective against VL and safe, even in rural settings (Thakur and Ahmed, 2001 ). Although AmB is not yet licensed for the treatment of VL in any country in the world, it is (unlike generic SSG) widely available as it is licensed for the treatment of fungal infections. There are no published data on the use of AmB against VL in Africa and it would be dangerous to assume that the drug will be as safe and effective against VL in Africa as it is against the disease in India. In Africa, the drug sensitivities of the parasites involved and the relevant characteristics of the human hosts probably differ from those in India (Berman et al., 1998) . Although liposomal amphotericin B (AmBisome TM ; Gilead Sciences, Foster City, CA), which is even better tolerated and more practical to use than conventional AmB (Sundar et al., 2004) , is used for the first-line treatment of VL in developed countries, it remains too expensive for most patients in the developing world (Bern et al., 2006) .
In Uganda, VL is only known to be endemic in Pokot county, in the northeastern district of Nakapiripirit, in a single focus that spreads into the neighbouring Kenyan district of West Pokot and affects the semi-nomadic pastoralists of the Pokot tribe. Although the VL in this area is known to be caused by Leishmania donovani, with Phlebotomus martini the primary and perhaps sole vector (Wykoff et al., 1969) , there are few epidemiological data on the disease in the Pokot. In this endemic focus, the proportion of VL patients co-infected with HIV is believed to be low, as, in an unlinked anonymous survey conducted by Médecins Sans Frontières (MSF) at Amudat Hospital, the main hospital for Nakapiripirit district, only three ( The drug was administered as a daily dose of 1 mg/kg bodyweight, with each dose given in a slow infusion, over 8-12 h, to improve tolerance. The total dose was 15 mg/kg, given on alternate days over a 30-day period in order to reduce the risk of nephrotoxicity. Renal-function tests could not be performed. If oedema was present, the dose was reduced by 10%, to 0.9 mg/kg. Patients were stimulated to drink abundantly. Access to safe drinking water was secured and oral-rehydration salts were distributed. If clinical dehydration was observed, intravenous rehydration, with 0.9% NaCl or Ringer's lactate solution, was initiated. Patients were given daily potassium and magnesium supplements, in addition to multi-vitamin, vitamin-C, folicacid and ferrous-sulphate tablets. All patients received supplementary feeding. Body temperatures were monitored daily and weights weekly. Antibiotic treatments for suspected bacterial infections and blood transfusions for severe anaemia were given, if necessary. Concomitant nephrotoxic medications were avoided.
Initial outcome was assessed, from the patient's general condition, spleen size, and haemoglobin concentration, on the 25th day of treatment. Initial cure was defined as the clearance of fever plus an improvement in general condition, a decrease in spleen size, and an increase in haemoglobin concentration. If the baseline symptoms persisted and/or there was no reduction in spleen size, a spleen aspirate was collected and checked for amastigotes, as a Giemsastained smear. If the aspirate was then found positive, the treatment was prolonged at the same dose until two successive negative spleen aspirates had been obtained (when the patient was defined as a slow responder). Treatment failures included both the non-responders (defined as those who showed neither clinical nor parasitological response to treatment) and the patients who had relapses, with VL diagnosed within 6 months of the initial cure. Definite cure was defined as the absence of relapse 6 months after hospital discharge. Although logistic constraints prevented active followup after discharge, most relapse cases would presumably have presented at Amudat Hospital again, as the hospital was the only centre offering treatment for VL in the whole endemic area during the study period. The frequencies of initial cure, in-hospital death and treatment failure were chosen as primary outcomes, whereas the variations in haemoglobin concentration and spleen size, between admission and the end of treatment, were taken as secondary outcomes.
The occurrence of adverse effects was assessed daily, during the clinician's rounds. In order to minimize any non-reporting bias resulting from the patients (most of whom speak Pokot as a first language) not under- , given at 20 mg/kg.day (without an upper limit) for 30 days. The baseline characteristics, outcomes and severe adverse effects among the patients treated with AmB were compared with those of the patients given Sb V . Data were entered in an Excel (Microsoft) spreadsheet by the clinician in charge. The database was subsequently cleaned by identifying aberrant data. Categorization of nutritional status was based either on weight-for-height, for girls who were ,137 cm tall and boys who were ,145 cm tall, or on body mass indexes (BMI). Weights-for-height that were ,70%, 70%-79%, 80%-89% and .89% of 'normal' (Anon. 1977) * On admission, the two cohorts were similar in terms of all the recorded characteristics (P.0.2) apart from anaemia; moderate-severe anaemia was significantly more common in the patients given Sb V (P,0.001).
(21.5%), epistaxis (14.3%), weakness (9.1%), oedema (5.3%) and vomiting (2.9%). The diagnosis of VL was based only on a DAT titre of at least 1:25,600 (181 cases) or on an amastigote-positive spleen aspirate (29 patients). Only branded AmB was given to 114 (54.3%) patients whereas 74 patients (35.2 %) were treated only with generic AmB and 22 (10.5%) received both products. Twenty-five (11.9%) patients with malaria, 22 (10.5%) with respiratory tract infections, and 21 (10.0%) with other bacterial infections (such as typhoid fever, otitis media, pharyngitis, brucellosis or dysentery) were given specific treatments for their accompanying infections.
Outcome of AmB Treatment
Of the 210 patients treated with AmB, 194, including one slow responder, were initially cured, resulting in an initial cure 'rate' of 92.4% (CI587.9%-95.6%). Ten of the patients died during their stay in the hospital, giving a case-fatality 'rate' of 4.8% (CI5 2.4%-8.8%). The causes of the 10 in-hospital deaths were bleeding (three patients), infectious complications (two), severe anaemia (one), cardiac failure (one), ileus (one) or unknown (two). Six patients relapsed, resulting in a treatment failure 'rate' of 2.9% (CI51.2%-6.4%). By the end of treatment, compared with their baseline values, the median haemoglobin concentration had increased by 1.4 g/dl and the mean spleen size had fallen by 5.3 cm. The case-fatality 'rates' among the patients treated with just branded AmB (5.3%), just generic AmB (5.4%), or a combination of the two products (0.0%) were not significantly different (P. 0.20). The patients given only the branded drug were more likely to fail treatment than the patients given only the generic drug but the difference did not quite reach statistical significance (4.4% v. 0.0%; P50.08).
Tolerance of AmB Treatment
The mean total dose of AmB administered was 13.6 mg/kg, corresponding to a mean The demographic characteristics of the cohort of 210 patients treated with AmB were similar to those of the historical cohort of 161 patients treated with Sb V (see Table 1 ). The clinical characteristics on presentation were also similar, with the exception that a higher proportion of patients in the Sb V group presented with moderate-severe anaemia, 49.1% of the patients given Sb V but 30.1% of those given AmB having ,7 g haemoglobin/dl (P,0.001). The frequencies of initial cure, in-hospital death and treatment failure were also similar in the two cohorts (Table 2) . One patient did not respond to Sb V and was switched to AmB, with a good clinical response. The treatment-attributable reduction in spleen size was significantly greater with Sb V than with AmB (6.8 v. 5.3 cm; P,0.001). Although the median increase in haemoglobin concentration was also greater with Sb V than with AmB (2.4 v. 1.4 g/dl; P50.032), the mean haemoglobin concentration recorded at the end of Sb V treatment was identical to that recorded at the end of the AmB treatment (9.7 g/dl; P50.13). The only adverse effect that required interruption of Sb V treatment was clinical pancreatitis, which occurred in two patients. Thus, only 1.2% (CI50.1%-4.4%) of the patients given Sb V and 1.9% (CI50.5%-4.8%) of those given AmB developed adverse effects that required the interruption of treatment (P.0.20).
DISCUSSION
For the treatment of VL in Amudat, Uganda, amphotericin B deoxycholate, either in its branded or generic form, appears as effective and safe as meglumine antimoniate. The case-fatality 'rate' seen among the AmB-treated patients in the present study (4.8%) was slightly higher than those recorded in India (Sundar et al., 2004; Thakur and Narayan, 2004) . In the trials of AmB among Indian cases of VL, however, strict exclusion criteria (such as any serious concurrent infection, neutropenia or severe anaemia) led to the exclusion of the most severe cases (Sundar et al., 2004; Thakur and Narayan, 2004) . In Africa, similar or higher case-fatality rates to those seen with AmB in Uganda (present study) have been reported among VL cases given other treatments (Veeken et al., 2000; Moore et al., 2001; Ritmeijer et al., 2001 Ritmeijer et al., , 2006 . In the present study, the frequency of severe adverse effects requiring the interruption of AmB treatment was low (1.9%), and an active search for adverse effects, by someone speaking the patients' first language, revealed only mild or moderate adverse-effects that decreased in severity during treatment.
In terms of clinical outcome and the incidence of severe adverse effects, the cohort treated with AmB was very similar to the historical cohort of patients treated with Sb V . The statistical comparison of these two cohorts does, however, have some limitations. Firstly, the two cohorts are consecutive and not concurrent. In the absence of randomization, discrepancies in the demographic or clinical characteristics of the patients might have remained unnoticed. Secondly, the physicians who assessed the patients changed during the study period, leading to possible between-cohort differences in the general management of the patients, the manual evaluation of spleen size, and/or the reporting of adverse effects.
The low frequency of failure (2.9%) observed in the present study indicates that AmB can be considered an effective drug for the treatment of VL in Uganda. As secondary resistance to AmB is believed to be an unlikely phenomenon in the absence of HIV co-infection (Bryceson, 2001 ), the few treatment failures that did occur are unlikely to be the result of such resistance in the local L. donovani. There are some indications that, to be effective, AmBisome needs to be given in higher doses in Africa than in India (Berman et al., 1998) . This might also be true for AmB, although the rarity of treatment failure in the present study indicates otherwise. As the present patients were not actively followed up after hospital discharge, the possibility that there were unrecorded cases of relapse remains. The number of such missed relapses was almost certainly small, however, given that Amudat Hospital was the only functional VL-treatment centre in the area during the study period. Although the frequency of treatment failure among the patients given Sb V was very similar to that among the patients given AmB, the reductions in spleen size and the increases in haemoglobin concentration during treatment were more marked in the Sb V group. The latter finding should be interpreted with caution, however, since the two cohorts differed in their mean haemoglobin concentrations on admission (Table 1) .
The relatively good tolerance of AmB observed in the present study is probably related to the long infusion time, the maintenance of adequate hydration and the supplementation of electrolytes. There is some evidence that a relatively slow infusion of AmB (4 h v. 45 min) reduces the occurrence of infusion-related adverse effects (Ellis et al., 1992) . Although the administration of AmB by continuous infusion over 24 h appears to reduce nephrotoxicity (Eriksson et al., 2001) , such long infusions were not feasible at Amudat Hospital. As it was also not possible to monitor renal function at the study hospital, AmB was given on alternate days, although there is no clear evidence that this reduces the risk of nephrotoxicity (Thakur et al., 1994) . The toxicity of AmB appears to vary with the patient population, the underlying clinical condition of the patients, the use of concomitant nephrotoxic drugs, and the mode of administration (Girmenia et al., 2001; Mayer et al., 1999) . Fortunately, acute renal failure appears to be rare among VL patients given the drug (Thakur et al., 1999) , although transient increases in creatinine concentrations are observed in up to 20% of such patients (Thakur et al., 1994) . AmB should be considered as a relatively safe drug in VL patients, provided that proper attention is given to the practical aspects of drug administration, including the permanent presence of nursing staff to monitor infusion flow. The workload of the medical and nursing team involved is clearly greater with slow infusions of AmB than with intramuscular injections of antimonial drugs given once daily. Moreover, the use of AmB is logistically more demanding, as it requires a cold chain and significant capacities for the transport and storage of intravenous fluids.
In conclusion, conventional AmB is an effective and reasonably safe drug for the treatment of VL in Uganda. Liposomal AmB would probably be even better tolerated and a more practical option, reducing the duration of the hospital stay (Bern et al., 2006) . A recent study conducted in Ethiopia showed that miltefosine could be an interesting therapeutic alternative for the treatment of VL in East Africa . Moreover, in clinical trials co-ordinated by the Drugs for Neglected Diseases initiative, the potential usefulness of paromomycin in the treatment of VL is currently being evaluated in several East African countries. The number of treatment options for VL, preferably using drugs in combination (Bryceson, 2001) , is therefore likely to increase in the coming years. In the mean time, the main priority in sub-Saharan Africa, where resistance to antimonials is still a negligible problem, is to ensure affordable and sustainable access to antimonials for the neglected populations suffering from VL (Berman et al., 1998; Yamey and Torreele, 2002) .
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